Genetic Markers That Identify TNF-Inhibitor Responders in Psoriasis

A first step toward personalized psoriasis therapy

Treatment of moderate-to-severe psoriasis changed dramatically with introduction of tumor necrosis factor α (TNF-α) inhibitors. However, these agents are very expensive and do not work in all patients. Investigators examined whether genetic polymorphisms in the TNF-promoter region and in the IL12B/IL23R genes might help to identify likely TNF-inhibitor responders. Psoriasis Area and Severity Index (PASI) scores were obtained prior to, and 3 and 6 months after, initiation of anti–TNF-inhibitor therapy in 109 psoriasis patients.

At 6 months, those with wildtype-238 and -1031 genotypes in the TNF-promoter region were more likely than patients with single nucleotide polymorphisms (SNPs) in those areas, although not significantly so, to achieve a…

Reviewing Author

Craig A. Elmets, MD

Disclosures

Consultant / Advisory board Astellas Pharmaceuticals

EquityVaxin

Grant / Research support NIH; NIH/NCI; Veteran’s Administration; Ferndale Laboratories; Kyowa Hakko Kirin Pharma, Inc.

Editorial boards Cancer Prevention Research; Photodermatology, Photoimmunology, & Photomedicine; UpToDate; eMedicine; Journal of Dermatological Sciences; JAMA Dermatology

Leadership positions in professional societies American Academy of Dermatology (Vice Chair, Committee on Science and Research); Photomedicine Society (Board of Directors)